Cite
HARVARD Citation
Gluz, O. et al. (n.d.). Five-year results of the prospective Phase III WSG PlanB trial confirm prognostic impact of 21-Gene Recurrence Score in high-risk HR+/HER2− early breast cancer (EBC) patients with 1-3 involved lymph nodes. Breast. pp. S93-. [Online].